Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP1 with or without Nivolumab in Advanced Solid Tumors (IGNYTE)
NCT03767348Phase 2Active, not recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- Sep 2017
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 5
01
Overview
A Phase 2 trial of vusolimogene oderparepvec in cutaneous melanoma (CM), solid tumor, non-melanoma skin cancer (NMSC), non-small cell lung cancer (NSCLC), sponsored by Replimune Group, Inc.. Started Sep 2017; status: active, not recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
cutaneous melanoma (CM)solid tumornon-melanoma skin cancer (NMSC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03767348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767348.